Table 2. Phenotype and genotype of the ErPCs from thalassemia patients employed in microRNA-210 and raptor analyses.

Patient number	α-globin mRNA (*)	β-globin mRNA (*)	γ-globin mRNA (*)	genotype
1	1.26	0.74	10.70	β0-39/β+-IVSI-110
2	1.27	1.14	5.13	β0-IVSI-1/β+-IVSI-6
3	0.72	2.05	1.80	β0-39/β0–39
4	1.09	0.95	2.14	β0-39/β0–39
5	1.11	0.96	3.05	β+-IVSI-6/β+-IVSI-110
6	1.04	1.13	3.39	β0-39/β+-IVSI-110
7	1.71	0.97	3.80	β0-39/β0–39
8	0.29	0.17	2.39	β0-39/β0-IVSI-6
9	1.13	2.35	4.29	β0-6(-A)/β+-IVSI-110

(*) fold increase in MTH-treated Th-ErPCs (with respect to untreated control cells)